Ocular Therapeutix Inc

NASDAQ:OCUL  
18.40
+0.29 (+1.60%)
Debt Financing / Related, Products, Regulatory

Ocular Says Entered Amendment To Existing Collaboration, Option And License Agreement With Regeneron

Published: 05/14/2020 22:08 GMT
Ocular Therapeutix, Inc. (OCUL) - Ocular Therapeutix Inc - on May 8 Entered Into an Amendment to Its Existing Collaboration, Option and License Agreement With Regeneron Pharmaceuticals.
Ocular - Co, Regeneron Have Adopted New Workplan to Transition Joint Efforts to Research & Development of Extended-delivery Formulation of Aflibercept.
Ocular Therapeutix Inc - in Addition, Amendment Provides for Modification of Terms of Option Previously Granted to Regeneron Under Agreement.
Ocular Therapeutix Inc - Amendment Also Revises Term and Termination Provisions of Agreement.
Ocular Therapeutix Inc - on May 13, 2020, Company Received Additional Interim Data Regarding Its Ongoing Phase 1 Clinical Trial of Otx-tki.
Ocular - Recently Amended Phase 1 Clinical Trial Protocol of Otx-tki and is Enrolling a Third Cohort of Subjects to Receive a Higher Dose of 600 Μg.
Ocular - Otx-tki Has Been Generally Well Tolerated & Has Been Observed to Have Favorable Safety Profile, With No Ocular Serious Adverse Events to Date.